Dianthus Therapeutics, Inc.NASDAQ: DNTH

Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)

· Issued by Dianthus Therapeutics, Inc. via GlobeNewswire

Summary by 6ix AI

Dianthus Therapeutics, a clinical-stage biotechnology company developing therapies for severe autoimmune diseases, granted stock options on July 1, 2026 to five newly-hired, non-executive employees as material inducements to accept employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key details

  • The non-qualified stock options cover an aggregate of 58,000 shares of common stock at an exercise price of $90.21 per share, with a 10-year term.
  • 25% of the options vest on the first anniversary of the vesting commencement date, with the rest vesting in equal monthly installments over the following 36 months.
  • The grants were approved by the company's independent Compensation Committee and are subject to the terms of the Dianthus Therapeutics, Inc. Equity Inducement Plan and a stock option agreement.

6ix AI wrote this summary from the release below and checked it against the release.

NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on July 1, 2026, to five newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 58,000 shares of the Company's common stock with a 10-year term and an exercise price of $90.21 per share. The options vest as to 25% on the first anniversary of the vesting commencement date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan, and the terms and conditions of a stock option agreement.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

Dianthus Therapeutics, Inc. on 6ix

Story so far

Earlier from Dianthus Therapeutics

Later from Dianthus Therapeutics

All Dianthus Therapeutics news releases